Short-term intensive insulin therapy at diagnosis in type 2 diabetes: Plan for filling the gaps

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 6, 2015, Pages 537-544

  Weng, Jianping ^a   Retnakaran, Ravi ^b   Ariachery C, Ammini ^c   Ji, Linong ^d   Meneghini, Luigi ^e   Yang, Wenying ^f   Woo, Jeong Taek ^g  

^a SUN YAT SEN UNIVERSITY   (China)

^b MOUNT SINAI HOSPITAL   (Canada)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d Ministry of Education Beijing   (China)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^g Kyung Hee University Hospital   (South Korea)

Author keywords

Consensus; Short term intensive insulin therapy; Type 2 diabetes

Indexed keywords

INSULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ARTICLE; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; EVIDENCE BASED MEDICINE; HUMAN; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT INDICATION; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; EARLY DIAGNOSIS; INSULIN RESISTANCE; METABOLISM; ORGANIZATION; PANCREAS ISLET BETA CELL; REMISSION; SECRETION (PROCESS);

ANIMALS; BIOMARKERS; CONGRESSES AS TOPIC; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; PRACTICE GUIDELINES AS TOPIC; REMISSION INDUCTION;

EID: 84941209108     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2603     Document Type: Article

References (78)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
2. Brouwer ES, West SL, Kluckman M, et al. Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. Pharmacoepidemiol Drug Saf 2012; 21: 920-928.
3. Veloso AG, Siersma V, Heldgaard PE, de Fine ON. Patients newly diagnosed with clinical type 2 diabetes mellitus but presenting with HbA1c within normal range: 19-year mortality and clinical outcomes. Prim Care Diabetes 2013; 7: 33-38.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
5. Hanefeld M, Bramlage P. Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. Curr Diab Rep 2013; 13: 342-349.
6. Owens DR. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther 2013; 15: 776-785.
7. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013; 19: 327-336.
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
9. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010; 33: 501-506.
10. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
11. Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012; 14: 762-767.
12. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742.
13. de Wit HM, Vervoort GM, Jansen HJ, de Grauw WJ, de Galan BE, Tack CJ. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). Diabetologia 2014; 57: 1812-1819.
14. Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab 2013; 15: 3-14.
15. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
16. Lamont BJ, Andrikopoulos S. Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology? J Endocrinol 2014; 221: T43-T61.
17. Dalle S, Burcelin R, Gourdy P. Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic beta-cell impairments in type 2 diabetes. Cell Signal 2013; 25: 570-579.
18. Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 4206-4216.
19. Maedler K. Beta cells in type 2 diabetes - a crucial contribution to pathogenesis. Diabetes Obes Metab 2008; 10: 408-420.
20. Karaca M, Magnan C, Kargar C. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention. Diabetes Metab 2009; 35: 77-84.
21. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004; 53(Suppl 3): S16-S21.
22. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
23. United Kingdom Prospective Diabetes Study (UKPDS). Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16). Diabetes 1995; 44: 1249-1258.
24. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
25. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-2237.
26. Alvarsson M, Sundkvist G, Lager I, et al. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab 2008; 10: 421-429.
27. Alvarsson M, Berntorp K, Fernqvist-Forbes E, et al. Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. Rev Diabet Stud 2010; 7: 225-232.
28. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. ß-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012; 35: 1406-1412.
29. Bhattacharya S, Ammini AC, Jyotsna V, Gupta N, Dwivedi S. Recovery of beta-cell functions with low-dose insulin therapy: study in newly diagnosed type 2 diabetes mellitus patients. Diabetes Technol Ther 2011; 13: 461-465.
30. Chandra ST, Priya G, Khurana ML, et al. Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes. Diabetes Technol Ther 2008; 10: 363-368.
31. Chen A, Huang Z, Wan X, et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012; 35: 474-481.
32. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31: 1927-1932.
33. Chon S, Oh S, Kim SW, Kim JW, Kim YS, Woo JT. The effect of early insulin therapy on pancreatic beta-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients. Korean J Intern Med 2010; 25: 273-281.
34. Hu Y, Li L, Xu Y, et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and beta-cell function in subjects with long-term remission. Diabetes Care 2011; 34: 1848-1853.
35. Huang Z, Wan X, Liu J, et al. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant alpha-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technol Ther 2013; 15: 859-869.
36. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356.
37. Kayashima T, Yamaguchi K, Konno Y, Nanimatsu H, Aragaki S, Shichiri M. Effects of early introduction of intensive insulin therapy on the clinical course in non-obese NIDDM patients. Diabetes Res Clin Pract 1995; 28: 119-125.
38. Kramer CK, Choi H, Zinman B, Retnakaran R. Determinants of reversibility of beta-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. Am J Physiol Endocrinol Metab 2013; 305: E1398-1407.
39. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27: 2597-2602.
40. Li Y, Xu W, Liao Z, Yao B, Huang Z, Weng J. The effect of continuous subcutaneous insulin infusion (CSSI) on glucose metabolism and induction on long-term glycemic control in newly diagnosed type 2 diabetic patients. Diabetes 2004; 53(Suppl. 2): A112. (Abstract)
41. Li Y, Zhu H, Yao B, et al. Influencing factors for the curative effects of short-term continuous subcutaneous insulin infusion on newly diagnosed type 2 diabetes [In Chinese]. Nat Med J China 2005; 85: 602-606.
42. Mu PW, Chen YM, Lu HY, et al. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev 2012; 28: 236-240.
43. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-1032.
44. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-1760.
45. Xu W, Li YB, Deng WP, Hao YT, Weng JP. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chin Med J (Engl) 2009; 122: 2554-2559.
46. Zhao QB, Wang HF, Sun CF, Ma AQ, Cui CC. Effect of short-term intensive treatment with insulin pump on beta cell function and the mechanism of oxidative stress in newly diagnosed type 2 diabetic patients [In Chinese]. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27: 1878-1879.
47. Li Y, Zeng L, Shi L, et al. The effects of early intensive therapy on islet beta cell function and long-term glycemia control in newly diagnosed type 2 diabetic patients with different fasting plasma glucose level [In Chinese]. Chin J Intern Med 2010; 49: 9-13.
48. Weng J, Liao Z, Xu W, et al. The effect of short-term continuous subcutaneous insulin infusion treatment on beta-cell function in newly diagnosed type 2 diabetic patients [In Chinese]. Chin J Diabetes 2003; 11: 10-15.
49. Zhu F, Ji L, Han X, et al. Induction of long-tern glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment [In Chinese]. Chin J Diabetes 2003; 11: 5-9.
50. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013; 1: 34.
51. Xu W, Weng J. Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes. J Diabetes 2013; 5: 268-274.
52. Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function. Diabetes Obes Metab 2012; 14(Suppl 3): 161-166.
53. Wajchenberg BL. Clinical approaches to preserve beta-cell function in diabetes. Adv Exp Med Biol 2010; 654: 515-535.
54. International Diabetes Federation. Global guideline for type 2 diabetes. 2012. http://www.idf.org/global-guideline-type-2-diabetes-2012. Accessed 15 December 2013.
55. Chinese Diabetes Society. Clinical guideline. 2013. Available at: http://www.cdschina.org/english/page.jsp?id=33#
56. Bailey CJ, Aschner P, Del PS, LaSalle J, Ji L, Matthaei S. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res 2013; 10: 397-409.
57. Meneghini LF. Early insulin treatment in type 2 diabetes: what are the pros? Diabetes Care 2009; 32(Suppl 2): S266-S269.
58. Davidson MB. Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation. Curr Opin Endocrinol Diabetes Obes 2009; 16: 107-112.
59. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010; 12: 65-71.
60. Chiasson JL. Early insulin use in type 2 diabetes: what are the cons? Diabetes Care 2009; 32(Suppl 2): S270-S274.
61. Liu L, Wan X, Liu J, Huang Z, Cao X, Li Y. Increased 1, 5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technol Ther 2012; 14: 756-761.
62. Liu J, Liu J, Fang D, et al. Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients. Endocr J 2013; 60: 725-732.
63. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 2010; 12: 909-915.
64. Chen H, Ren A, Hu S, Mo W, Xin X, Jia W. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract 2007; 75: 327-332.
65. Son JW, Jeong HK, Lee SS, et al. The effect of early intensive insulin therapy on body fat distribution and beta-cell function in newly diagnosed type 2 diabetes. Endocr Res 2013; 38: 160-167.
66. Del Prato S, Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 2004; 36: 775-781.
67. Dutton H, Rowan MS, Liddy C, et al. Patient perspectives on discharge from specialist type 2 diabetes care back to primary care: a qualitative study. Can J Diabetes 2014; 38: 191-197.
68. Skinner T, Allen P, Peach E, et al. Does the shortage of diabetes specialists in regional and rural Australia matter? Results from Diabetes MILES--Australia. Diabetes Res Clin Pract 2013; 100: 222-229.
69. Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in beta-cell function. Diabetes Care 2014; 37: 116-123.
70. Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin 2011; 27: 1169-1174.
71. Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract 2011; 65: 408-414.
72. Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Invest Med 2007; 55: 62-68.
73. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care 2009; 32: 1789-1795.
74. Opsteen C, Qi Y, Zinman B, Retnakaran R. Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. J Eval Clin Pract 2012; 18: 256-261.
75. Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med 2011; 28: 628-642.
76. Hoerger TJ, Zhang P, Segel JE, Kahn HS, Barker LE, Couper S. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care 2010; 33: 1933-1939.
77. Keating CL, Dixon JB, Moodie ML, et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care 2009; 32: 567-574.
78. Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1-357, iii.